LEAD Therapeutics Announces New Antibiotic

LEAD Therapeutics has released data on LT-29, a novel glycopeptide antibiotic that was effective against many of the most common antibiotic resistant bacteria. LT-29 is in preclinical development to treat serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. LEAD presented data about LT-29 at the recent 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). More details...